Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 113

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4A
Chunk 113
---
 compensation expenses, approximately $1.5 million of
depreciation and amortization of property, plant and equipment and right-of-use-assets and approximately $1.0 million of amortization
of intangible assets.

Cash used in operating activities for the year ended December 31,
2023 was approximately $21.6 million and primarily reflects our overall loss of approximately $26.0 million, as adjusted downwards to
eliminate certain non-cash items that were taken into account in calculating, and that increased, our overall loss, including approximately
$1.9 million of share-based compensation expenses, approximately $1.6 million of depreciation expenses, approximately $1.0 million amortization
of intangible assets and interest received of approximately $0.9 million. These downwards adjustments to cash used were partially offset
by approximately $0.7 million of non-cash net financing income and approximately $0.4 million of changes in asset and liability items,
mainly due to an increase in other receivables, partially offset by increase in trade payables and payroll accrual balances.

70

Cash Provided by (Used In) Investing Activities

Cash provided by investing activities was approximately $9.6 million
for the year ended December 31, 2024, that primarily reflects cash proceeds from short-term bank deposits, net of investment in short-term
bank deposits of approximately $10.2 million, partially offset by cash used for the purchase of property, plant and equipment of approximately
$0.6 million.

Cash used in investing activities was approximately $4.5 million
for the year ended December 31, 2023. That primarily reflects cash investment in bank deposits of approximately $10.2 million and cash
used for the purchase of property, plant and equipment of approximately $0.8 million, offset by approximately $6.9 million of proceeds
from the sale of marketable securities, net of net cash invested in the purchase of marketable securities of approximately $0.5 million.

Cash Provided by Financing Activities

Cash provided by financing activities was approximately $4.7 million for the year ended
December 31, 2024. That was primarily attributable to proceeds from issuance of ordinary shares, pre-funded warrants and warrants
of approximately $5.5 million and to the net proceeds from government grants of approximately $0.2 million, partially offset by approximately
$0.9 million for the repayment of lease liabilities and by approximately $0.3 million for the repayment of government grants.